Objectives: To test miR-223 upregulation during gastric (intestinal-type) and Barrett esophageal carcinogenesis.
Methods: miR-223 expression was assessed by quantitative reverse transcription polymerase chain reaction in a series of 280 gastroesophageal biopsy samples representative of the whole spectrum of phenotypic changes involved in both carcinogenetic cascades. The results were further validated by in situ hybridization on multiple tissue specimens obtained from six surgically treated gastroesophageal adenocarcinomas. miR-223 expression was also assessed in plasma samples from 30 patients with early stage (ie, stages I and II) gastroesophageal adenocarcinoma and relative controls.
Results: In both gastric and esophageal models, miR-223 expression significantly increased along with the severity of the considered lesions (analysis of variance, P < .001). Among atrophic gastritis and long-segment Barrett esophagus samples, miR-223 overexpression was significantly associated with the score of intestinal metaplasia. miR-223 plasma levels were significantly upregulated in patients with cancer compared with controls (t test, both P < .001).
Conclusions: miR-223 early upregulation observed in tissue samples and its diagnostic value in discriminating patients with early adenocarcinoma by plasma testing provide a solid rationale for further exploring the diagnostic reliability of this microRNA as a novel biomarker in gastroesophageal adenocarcinoma secondary prevention strategies.
Despite recent advances in personalized targeted therapy, intestinal-type gastric cancer (GC) and Barrett esophageal adenocarcinoma (BAc) are still two of the main leading causes of cancer-related death worldwide. 1, 2 Both conditions are triggered by longstanding inflammation (due to Helicobacter pylori infection and gastroesophageal reflux, respectively), resulting in a metaplastic transformation of the native mucosa. 3 The new metaplastic epithelia are the cancerization field in which gastroesophageal intraepithelial and invasive neoplastic lesions develop. 4, 5 In fact, both conditions follow a multistep
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progression throughout nondysplastic metaplastic glands to low-grade intraepithelial neoplasia (LG-IEN, formerly LG dysplasia) and high-grade IEN (HG-IEN, formerly HG dysplasia), culminating in invasive adenocarcinoma. 5, 6 The molecular landscapes associated with GC and BAc initiation are gradually becoming elucidated, but no efficient and effective biomarkers are available for secondary prevention strategies. 3 Among others, microRNAs (miRNAs) have a remarkable intrinsic stability in both formalin-fixed, paraffinembedded (FFPE) tissues and body fluids, which favorably sustains their diagnostic and prognostic clinical impact. 7 miR-223 has been extensively studied in the GC setting, where it is significantly upregulated in GC tissues compared with surrounding mucosa. [8] [9] [10] Moreover, miR-223 upregulation has been strongly associated with H pylori infection, 11, 12 suggesting its early driving role as "oncomiR" on gastric mucosa. This is confirmed by its early increase in chronic nonatrophic and atrophic gastritis samples. 13 Furthermore, it has been reported that circulating miR-223 is significantly overexpressed in patients with GC, even at early stages. [14] [15] [16] [17] A significant miR-223 overexpression also has been observed for BAc samples compared with normal adjacent mucosa, 18 and a consistent stepwise miR-223 increment characterizes Barrett carcinogenesis. 19, 20 Recently, the serum exosomal concentration of miR-223 has been proposed as an innovative noninvasive biomarker to be tested in the diagnosis and therapy monitoring of esophageal adenocarcinoma. 21 This study focused on the involvement of miR-223 over the whole series of nonneoplastic and neoplastic phenotypic changes occurring in both intestinal-type gastric (also known as the Correa cascade) and Barrett carcinogenesis, focusing on their early phases. miR-223 expression was profiled by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in a large series of FFPE biopsy samples and by miRNA in situ hybridization on surgical tissue specimens. A further series of plasma samples obtained from patients with early stage gastroesophageal adenocarcinoma was also analyzed to test miR-223 diagnostic value as a noninvasive biomarker.
Materials and Methods

Patients
A total of 304 histopathologic and 60 plasma samples from 306 patients (168 men and 138 women; mean 6 SD age, 66.4 6 9.4 years; all white) were considered and included in this study.
All histopathologic samples were retrospectively collected from the files of the Surgical Pathology Unit at the University of Padua and from the Veneto Region's multicenter Barrett Esophagus Registry (EBRA, Padua Unit). 22 Investigation has been conducted in accordance with the ethical standards, the Declaration of Helsinki, and national and international guidelines and has also been approved by the authors' institutional review board (3343/AO/14 and 3344/AO/14).
In total, 240 endoscopic biopsy samples from different biopsy sets were considered for the qRT-PCR study. The tissue samples were representative of each of the phenotypic lesions in the gastric (intestinal-type) and esophageal (Barrett-related) carcinogenic cascades. 3 Furthermore, 20 normal antral gastric mucosa and 20 normal esophageal mucosa samples were obtained from 20 patients undergoing endoscopy for functional dyspepsia and were considered for control purposes. No H pylori-positive sample was considered in the analysis.
Twenty-four samples obtained from six gastrectomies/ esophagectomies for well-differentiated to moderately differentiated adenocarcinoma (three patients with GC and three patients with BAc; mean 6 SD age, 71.2 6 8.4 years) were used for the in situ hybridization analysis.
A series of 80 plasma samples were retrieved from the archives of the Gastroenterology Unit at the Istituto Oncologico Veneto (Padua). Plasma samples were collected from 20 dyspeptic patients with no significant lesion at histology (the Sydney system biopsy protocol was applied and further biopsy specimens were obtained from the esophageal mucosa), 15 patients with atrophic gastritis (OLGA stages I-III), 15 patients with GC (all stages I-II), 15 patients with long-segment Barrett esophagus with no histologically proven dysplastic lesion, and 15 patients with BAc (all stages I-II).
RNA Isolation
Biopsy samples were manually microdissected to ensure that each sample contained at least 70% of normal mucosa/lesion cells. The percentage of the target lesion as obtained by manual microdissection was further validated on an adjunctive H&E histology section. Total RNA was extracted using the RecoverAll kit (Ambion, Austin, TX) according to the manufacturer's instructions.
In plasma samples, 500 mL human plasma was thawed on ice and lysed with an equal volume of 2Â denaturing solution (Ambion). To allow for normalization of sampleto-sample variation in RNA isolation, synthetic Caenorhabditis elegans miRNAs cel-miR-39, cel-miR-54, and cel-miR-238 (synthetic RNA oligonucleotides synthesized by Qiagen, Hilden, Germany) were added (as a mixture of 7 pg/pL of each oligonucleotide) to each denatured sample (ie, after combining the plasma sample with denaturing solution) with the exception of cel-miR-238, which was added after complementary DNA assembly. RNA was isolated using the mirVana PARIS kit (Ambion) following the manufacturer's protocol for liquid samples. RNA was eluted with 50 mL RNase-free H 2 O.
qRT-PCR Analysis
The NCode miRNA qRT-PCR method (Invitrogen, Carlsbad, CA) was applied to detect and quantify mature hsa-miR-223 according to the manufacturer's instructions, using an ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA). Normalization was done with the small nuclear RNA U6B. All reactions were run in duplicate, including no-template controls. The fold difference for each sample was obtained using the DDCt method.
For plasma samples, normalization was reached using a median normalization procedure, as previously described with minor modifications. 24 In the Correa model, miR-223 expression significantly increased along with the severity of the lesions considered (analysis of variance [ANOVA], P < .001; Figure 1A ). Compared with normal H pylori-negative antral mucosa, miR-223 upregulation was significant in atrophic gastritis (t test, P < .001), LG-IEN (t test, P < .001), HG-IEN (t test, P < .001), and intestinal-type GC (t test, P < .001). A significant miR-223 upregulation was observed in LG-IEN vs atrophic gastritis (t test, P < .001), HG-IEN vs atrophic gastritis (t test, P < .001), HG-IEN vs LG-IEN (t test, P < .001), GC vs atrophic gastritis (t test, P < .001), GC vs LG-IEN (t test, P < .001), and GC vs HG-IEN (t test, P < .001). Of note, only two (10%) of 20 GCs were characterized by a relatively low miR-223 expression.
OLGA staging has been internationally accepted as a reliable method to rank the GC risk according to the extent/ severity of gastric atrophy. [26] [27] [28] In fact, cross-sectional and long-term follow-up trials conducted in various epidemiologic settings have consistently associated OLGA stages III to IV with a higher risk of GC. 23, 27, 28 Of note, among atrophic gastritis samples, miR-223 was significantly upregulated in more advanced stages of the disease (t test, P ¼ .005; Figure 1B ), further supporting an early miR-223 commitment in gastric mucosa transformation. As observed in the gastric setting, a significant miR-223 overexpression was observed during Barrett carcinogenesis (ANOVA, P < .001; Figure 1C ). Compared with naive esophageal mucosa, miR-223 upregulation was significant in Barrett mucosa (t test, P ¼ .007), LG-IEN (t test, P < .001), HG-IEN (t test, P < .001), and BAc (t test, P < .001). A significant miR-223 upregulation was observed in LG-IEN vs Barrett mucosa (t test, P ¼ .001), HG-IEN vs Barrett mucosa (t test, P < .001), HG-IEN vs LG-IEN (t test, P < .001), BAc vs Barrett mucosa (t test, P < .001), BAc vs LG-IEN (t test, P < .001), and BAc vs HG-IEN (t test, P ¼ .023). Both HG-IEN and BAc lesions showed a significantly higher expression in comparison to the other analyzed samples.
Among the different types of metaplastic lesions occurring in Barrett mucosa, samples characterized by 75% or more of glands with intestinal metaplasia showed higher miR-223 expression in comparison to samples with gastric metaplasia (t test, P ¼ .037; Figure 1D ).
miR-223 Is Expressed in Both Epithelia and Inflammatory Cells
To explore cellular commitment in miR-223 deregulation, miR-223 expression was also tested by ISH in 24 tissue samples obtained from six surgically treated gastroesophageal adenocarinomas.
A significant overexpression in both paired primary HG-IEN and invasive adenocarcinoma compared with normal gastric/esophageal mucosa was observed in all tested samples Image 1A . miR-223 expression was detectable as a granular cytoplasmic blue staining consistently expressed by neoplastic epithelia. Normal gastric antral mucosa showed a negative or faint staining, whereas squamous esophageal mucosa was characterized by a moderate miR-223 staining at the basal epithelial layer. Of note, a low to medium miR-223 expression was also observed in the peritumoral inflammatory infiltrate Image 1B and Image 1C . Most inflammatory cells were stained, with a relatively higher expression observed in monocytes.
Circulating miR-223 Is an Early Biomarker of Gastroesophageal Mucosa Transformation
The higher miR-223 expression in both primary GC and BAc tissues could influence miR-223 expression in the plasma of these patients. We thus analyzed miR-223 plasma levels in a series of 80 plasma samples obtained from early stage (stages I and II) gastric and esophageal adenocarcinoma and relative controls.
Compared with 20 (control) dyspeptic patients, patients with GC and BAc showed a higher plasma miR-223 expression. Plasma miR-223 concentrations were significantly higher in patients with GC and BAc than in patients with atrophic gastritis (OLGA stages I-III; t test, P < .001) or patients with long-segment Barrett esophagus (t test, P < .001) Figure 2 . No significant differences were observed in miR-223 expression between the plasma samples obtained from dyspeptic patients and those obtained from patients with atrophic gastritis or long-segment Barrett esophagus (t test, both P ¼ ns).
Discussion
Expanding the information on the molecular alterations involved in gastric and esophageal carcinogenesis could provide new key molecular elements for designing secondary prevention strategies based on a biological rationale. 3, 5, 6 This study focuses on a known gastric and esophageal oncomiR, miR-223. [8] [9] [10] 13, [18] [19] [20] The significant overexpression observed in both gastric and esophageal intestinal metaplasia consistently associates miR-223 upregulation with the earliest stages of both oncogenetic cascades. This evidence further prompts consideration of miR-223 as a promising tool in the early assessment of gastric and esophageal adenocarcinoma. H pylori gastritis has been significantly associated with miR-223 overexpression, which significantly drops following the bacterium eradication. 13 This finding could be partly explained by the role of miR-223 as myeloidspecific miRNA involved in the fine-tuning of the inflammatory response. 29, 30 As a consequence, miR-223 upregulation could result, at least in part, from the inflammatory infiltrate (granulocytes, among the others) triggered by the H pylori infection. other hand, ISH results in the epithelial compartment were consistent with qRT-PCR and literature data, further supporting a key role of miR-223 in gastric mucosa transformation. Gastritis staging (OLGA system) is internationally accepted in discriminating patients with gastritis according to their different GC risk. 27 The significant upregulation of miR-223 observed in OLGA stages III/IV is consistent with the increased GC risk associated with these advanced gastritis stages.
As previously observed, 19, 20 miR-223 was significantly upregulated during Barrett carcinogenesis. In the past 10 years, however, the histologic definition of Barrett mucosa has been debated, particularly regarding the phenotype of its metaplastic columnar epithelium. 22, 31, 32 We previously described miRNA profiling characterizing both nonintestinalized (ie, cardiac gastric type) and intestinalized columnar metaplasia in the spectrum of Barrett histology and demonstrated that a consistent miRNA expression signature underlines both types of metaplasia. 33 Here, we observed a slight miR-223 overexpression in intestinalized mucosa samples, further supporting a progressive deregulation along the path from squamous to nonintestinalized to intestinalized metaplasia. This is in line with the hypothesis of a transformation from a nonintestinalized (earlier) to an intestinalized (more advanced) Barrett phenotype.
5
A recent meta-analysis pinpointed miR-223's value as a novel biomarker in the early diagnosis of patients with cancer. 15 This could be explained by (1) the remarkable change occurring in the cancer microenvironment, in which many tumor-associated cells, such as dendritic cells, macrophages, myeloid cells, and T cells, could release exosomes, which are responsible for shuttling miRNAs to other cells or in the bloodstream, 34 and (2) the early miR-223 dysregulation in epithelial cells and the release of miR-223-rich exosomes in the blood. 21 In accordance with previous data, also in the present study, the circulating levels of miR-223 were significantly higher in patients with early cancer than in those without cancer (ie, H pylori gastritis and Barrett esophagus). Since gastritis, Barrett mucosa, and early cancers share a similar inflammatory background, the increased levels of circulating miR-223 of patients with early cancer should be confidently ascribed to the oncomiR's overexpression.
In conclusion, in a large series of well-profiled phenotypic lesions, our findings confirmed that miR-223 upregulation plays a key pathogenic role starting from the earliest phenotypic changes of gastroesophageal carcinogenesis. The reliability of miR-223 plasma testing in discriminating patients with early cancer prompts further investigation of the diagnostic consistency of this miRNA as a novel biomarker to be applied in both gastric cancer and Barrett adenocarcinoma secondary prevention strategies.
